Frequently Asked Questions
In 2022, the global Non-alcoholic Steatohepatitis (Nash) Biomarkers market was estimated to be worth USD 0.91 billion.
The Non-alcoholic Steatohepatitis (Nash) Biomarkers market is estimated to grow at a 23.10% CAGR between 2023 and 2030, reaching USD 3.91 billion in 2030.
In 2022, the serum biomarkers segment held the most significant market share at 32.51%.
In 2022, the pharma and CRO industry end-use segment held the biggest market share of 40.58% and is predicted to grow at the fastest rate during the forecast period.
The global Non-alcoholic Steatohepatitis (Nash) Biomarkers market research report is divided into the following categories: By Type, By End-use
North America held the most significant market share of 59.53% in 2022.
The top players include GENFIT, Prometheus Laboratories, and Siemens Medical Solutions USA, Inc. Other major players include BioPredictive, Quest Diagnostics, and AstraZeneca.
The increased demand for non-invasive diagnostic approaches for NASH detection and the launch of new diagnostic tests are driving market growth.
The challenges limiting the market growth are a lack of standardization and limited clinical validation.
The market’s primary opportunities are digital health and remote monitoring, biomarker panels, and multiomics approaches.